Indaptus Therapeutics, Inc.

NASDAQ:INDP

Biotechnology

Healthcare
$3.29 -2.21%

-$0.03 today

Market cap
$372.57M
Beta
1.14
P/E (TTM)
-0.2
EPS (TTM)
-$8.70
52W Low $0.92High $8.69

Volume 0.17M

Average 0.97M

INDP Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Indaptus Therapeutics, Inc.NASDAQ: INDP

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $0.

Context

  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Cost of Revenue vs competitors

How INDP compares with its peers on the latest reported figures

  • INDP's LTM Mar 2026 cost of revenue of $0 is the highest of the 2 companies compared; the peer median is $0.
INDP Competitors Peer median
Cost of Revenue for INDP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$0 ———
AZTRAzitra, Inc.LTM Jun 2026$0 ———
Peer median (excluding INDP) $0———

Competitors are the stored peer set for INDP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development2.52M6.32M7.62M7.25M9.34M
Selling, General & Admin5.21M8.59M8.76M8.11M10.49M
Operating Expenses7.73M14.91M16.38M15.37M19.83M
Depreciation & Amortization1.4K1.78K1.28K7350
EBITDA(7.71M)(14.32M)(15.42M)(15.02M)(20.85M)
EBITDA Margin—————
Operating Income(7.73M)(14.91M)(16.38M)(15.37M)(19.83M)
Operating Margin—————
Interest Income17.72K588.11K000
Interest Expense00000
Other Income / Expenses17.72K588.11K955K343.72K(1.02M)
Income Before Tax(7.71M)(14.32M)(15.42M)(15.02M)(20.85M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(7.71M)(14.32M)(15.42M)(15.02M)(20.85M)
Net Margin—————
EPS (Basic)(1.89)(1.73)(1.84)(1.61)(21.58)
EPS (Diluted)(1.89)(1.73)(1.84)(1.61)(21.58)
Weighted Avg Shares4.09M8.26M8.4M9.36M966.12K
Weighted Avg Shares (Diluted)4.09M8.26M8.4M9.36M966.12K

Indaptus Therapeutics, Inc.

NASDAQ:INDP

Intrinsic Alpha fair value

Locked

Current Price

$3.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.